Cerus Corporation Stock Price and Value Analysis

Cerus Corporation (NasdaqGM:CERS) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Cerus Corporation to reach your target.

Target type

CERS Free Cash Flow Trend

Free Cash Flow trendline for CERS
Free Cash Flow trendline for Cerus Corporation

Hmm, we can't give any reliable projection for Cerus Corporation's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This company has stable growth.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the CERS Numbers

CERS Price
(Cerus Corporation stock price per share)
$2.65
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Medical Devices stocks
[?] Cash Yield -9.57%
[?] Free Cash Flow Jitter 19%

Insider Activity Summary

In the six months to 2026-11-10, no insider bought shares, and 5 insiders sold in 8 trades, about $841 thousand.

The six months before that had 0 buys and 14 sales.

Recent Insider Activity

Open-market buys and sells reported by Cerus Corporation's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-08-17 Jensen Chrystal (Chief Legal Officer) Sell 30,000 $2.98
2026-07-16 Jayaraman Vivek K (Chief Executive Officer) Sell 16,666 $3.16
2026-06-30 Green Kevin Dennis (Chief Financial Officer) Sell 33,676 $2.94
2026-06-30 Jensen Chrystal (Chief Legal Officer) Sell 24,329 $2.94
2026-06-30 Greenman William Mariner (President and CEO) Sell 101,919 $2.94
2026-06-30 Jayaraman Vivek K (Chief Operating Officer) Sell 42,359 $2.94
2026-06-09 BJERKHOLT ERIC Sell 20,454 $2.60
2026-05-29 Jayaraman Vivek K (Chief Operating Officer) Sell 16,667 $3.00
2026-05-01 Jayaraman Vivek K (Chief Operating Officer) Sell 16,667 $3.00
2026-03-12 Jayaraman Vivek K (Chief Operating Officer) Sell 165,200 $1.66

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 17,717,716 shares shorted. With 195,348,160 shares available for purchase and an average trading volume over the past 10 trading days of 1,222,940, it would take at least 14.5 days for all of the short holders to cover their shorts.

What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 1020214 -14.7
2010 1020214 -15.2
2011 1020214 -16.3
2012 1020214 -14.4
2013 1020214 -27.4
2014 1020214 -40.8
2015 1020214 -51.9
2016 1020214 -54.4
2017 1020214 -53.1
2018 1020214 -32.2
2019 1020214 -67.8
2020 1020214 -44.3
2021 1020214 -36.5
2022 1020214 -28.5
2023 1020214 -46.8
2024 1020214 9.0
2025 1020214 2.0

Download the yearly data as CSV.

Price Versus Our Estimated Value

Free cash flow was positive in 2 out of 17 reported years for Cerus Corporation, using only its current SEC filer.

Free cash flow is fairly steady from year to year, with a variability measure of 19%.

We do not estimate a fair value for Cerus Corporation while its free cash flow growth is not positive, so there is no value comparison here.

Dividends are not in our data for Cerus Corporation.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 100% below the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1020214.

Each figure on this page comes from that filer.

Risks to This Analysis

  • Free cash flow was negative in 15 of the 17 years we have.
  • We have no value estimate for this stock, so no price comparison is made.
  • This page's data was last updated on 2026-09-18. Prices and filings may have changed since.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in CERS

Does Cerus Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: CERS

This example shows how we apply the Trendshare checklist to CERS: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 2.65
    • Market cap: $534M
    • EPS: -0.03
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: -9.6%
    • Date checked: Sep 18, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.